[{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"K-NK002","moa":"CD16","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Tedopi","moa":"||Killer T-cell","graph1":"Oncology","graph2":"Undisclosed","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ European Investment Bank","highestDevelopmentStatusID":"1","companyTruncated":"OSE Immunotherapeutics SA \/ European Investment Bank"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Vaccinia virus Copenhagen Strain","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Undisclosed","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Transgene \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : K-NK002

                          Therapeutic Area : Oncology

                          Study Phase : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : IND supports the Company’s planned NK-REALM Phase 1/2 study which will evaluate K-NK002 in 63 patients with blood cancer undergoing a haploidentical hematopoietic stem cell transplant (HSCT).

                          Product Name : K-NK002

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 04, 2020

                          Lead Product(s) : K-NK002

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Study Phase : Undisclosed

                          Sponsor : Kreos

                          Deal Size : $5.9 million

                          Deal Type : Financing

                          Details : The conversion of a sizeable portion of Kiadis's loan into a convertible structure supports its recent refocus on its proprietary K-NK platform.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $5.9 million

                          January 10, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Kreos

                          Deal Size : $5.9 million

                          Deal Type : Financing

                          Sanofi Company Banner

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Sanofi and Innate entered into a research collaboration and licensing agreement for the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate Pharma and Sanofi’s proprietary bispecific antibody format as well ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $26.6 million

                          December 19, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Sanofi

                          Deal Size : $1,466.5 million

                          Deal Type : Expanded Collaboration

                          blank

                          04

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : VVcopTK-RRis a large capacity Vaccinia virus Copenhagen strain genetically modified with the double deletion TK-RR- which restricts the viral replication to tumor cells only.

                          Product Name : VVcopTK-RR-

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 06, 2021

                          Lead Product(s) : Vaccinia virus Copenhagen Strain

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : This loan will help expand the clinical development of Tedopi® in combination with a checkpoint inhibitor in additional cancer indications.

                          Product Name : OSE2101

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          February 15, 2021

                          Lead Product(s) : Tedopi,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : European Investment Bank

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank